Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases
- Companies to partner on process development, analytical development, and large-scale manufacturing for late-stage clinical and commercial supply
- Process development and manufacturing to be located in Lonza's cGMP facility in Houston, Texas